ALPA Stock Overview
Engages in the manufacture and sale of pharmaceutical finished dosage forms in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Alpa Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹116.08 |
| 52 Week High | ₹144.50 |
| 52 Week Low | ₹69.90 |
| Beta | 1.09 |
| 1 Month Change | -13.69% |
| 3 Month Change | 2.54% |
| 1 Year Change | 6.74% |
| 3 Year Change | 40.36% |
| 5 Year Change | 483.32% |
| Change since IPO | 110.48% |
Recent News & Updates
Recent updates
Alpa Laboratories Limited (NSE:ALPA) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 03
Increases to Alpa Laboratories Limited's (NSE:ALPA) CEO Compensation Might Cool off for now
Sep 22Alpa Laboratories Limited's (NSE:ALPA) Shares Bounce 32% But Its Business Still Trails The Market
Sep 06We Think That There Are Issues Underlying Alpa Laboratories' (NSE:ALPA) Earnings
Jun 08Cautious Investors Not Rewarding Alpa Laboratories Limited's (NSE:ALPA) Performance Completely
Jun 03Here's Why We Think Alpa Laboratories (NSE:ALPA) Might Deserve Your Attention Today
Dec 14Shareholders May Not Be So Generous With Alpa Laboratories Limited's (NSE:ALPA) CEO Compensation And Here's Why
Sep 23Here's Why Alpa Laboratories (NSE:ALPA) Has Caught The Eye Of Investors
Aug 26Is Alpa Laboratories (NSE:ALPA) A Risky Investment?
Jan 19Is Now The Time To Put Alpa Laboratories (NSE:ALPA) On Your Watchlist?
Jun 17If You Like EPS Growth Then Check Out Alpa Laboratories (NSE:ALPA) Before It's Too Late
Feb 23Alpa Laboratories' (NSE:ALPA) Earnings Aren't As Good As They Appear
Nov 24Here's Why I Think Alpa Laboratories (NSE:ALPA) Might Deserve Your Attention Today
Oct 05Do Alpa Laboratories's (NSE:ALPA) Earnings Warrant Your Attention?
May 31With EPS Growth And More, Alpa Laboratories (NSE:ALPA) Is Interesting
Jan 28Shareholder Returns
| ALPA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.6% | 3.2% | 2.4% |
| 1Y | 6.7% | 18.4% | 5.8% |
Return vs Industry: ALPA underperformed the Indian Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: ALPA matched the Indian Market which returned 5.8% over the past year.
Price Volatility
| ALPA volatility | |
|---|---|
| ALPA Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: ALPA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ALPA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 410 | Paresh Chawla | www.alpalabs.in |
Alpa Laboratories Limited engages in the manufacture and sale of pharmaceutical finished dosage forms in India. The company offers ethical, generic, and over the counter pharmaceutical products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, creams, gels, and ointments for human and veterinary use. It also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations.
Alpa Laboratories Limited Fundamentals Summary
| ALPA fundamental statistics | |
|---|---|
| Market cap | ₹2.44b |
| Earnings (TTM) | ₹208.02m |
| Revenue (TTM) | ₹972.97m |
11.7x
P/E Ratio2.5x
P/S RatioIs ALPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPA income statement (TTM) | |
|---|---|
| Revenue | ₹972.97m |
| Cost of Revenue | ₹617.48m |
| Gross Profit | ₹355.49m |
| Other Expenses | ₹147.47m |
| Earnings | ₹208.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 9.89 |
| Gross Margin | 36.54% |
| Net Profit Margin | 21.38% |
| Debt/Equity Ratio | 1.4% |
How did ALPA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 22:00 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpa Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |